XHEL
NXTMH
Market cap74mUSD
Oct 09, Last price
9.20EUR
1D
2.11%
1Q
-6.31%
Jan 2017
-40.76%
IPO
-98.48%
Name
Nexstim Oyj
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nexstim Plc, a medical technology enterprise, specializes in the creation and global distribution of non-invasive brain stimulation technologies, with operations spanning Finland, Europe, North America, and other international markets. Central to its offerings is the proprietary SmartFocus technology, featuring 3D navigation, which underpins its navigated transcranial magnetic stimulation (TMS) approach utilized for both therapeutic interventions and diagnostic assessments. The company provides two distinct systems: the NBT system, a navigated brain therapy solution designed for addressing major depression and chronic neuropathic pain, and the NBS system, a navigated brain stimulation device engineered for precise pre-surgical mapping of the brain's speech and motor cortices. Nexstim predominantly sells its NBS systems to academic institutions and teaching hospitals. Established in 2000, Nexstim Plc's corporate headquarters are located in Helsinki, Finland.
Key people
Mikko Karvinen
Chief Executive Officer, Member of the Management Board · since 2020
Joonas Juokslahti
Chief Financial Officer, Member of the Management Board · since 2020
Hanna Kotola
Vice President Legal, Quality and Regulatory Affairs; Member of the Management Team · since 2017
Henri Hannula
Chief Commercial Officer · since 2025
Gustaf Jarnefelt
Vice President, Research & Development; Member of the Management Team · since 2008
Jarmo Laine
Vice President, Medical Affairs, Member of the Management Team · since 2013
Martin Forss
Member of the Board · since 2019
Timo Hilden
Member of the Board · since 2021
Chairman of the Board · since 2019
Tero Weckroth
Member of the Board · since 2021
Headquarters & legal address
Elimäenkatu 9 B
00510 HELSINKI
HELSINKI FI-00510
FI
00510 HELSINKI
HELSINKI FI-00510
FI
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||